Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensions

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e153-

  Carver, Kyle ^a   Ming, Xin ^a   Juliano, Rudolph L ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARGINYLGLYCYLASPARTIC ACID; LIPID; NANOCARRIER; OLIGONUCLEOTIDE; POLYMER;

A375 CELL LINE; ARTICLE; CELL DENSITY; CELL SURFACE; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG FORMULATION; DRUG PENETRATION; DRUG UPTAKE; ENDOSOME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERCELLULAR SPACE; MICROMETASTASIS; MONOLAYER CULTURE; MULTICELLULAR TUMOR SPHEROID; OLIGONUCLEOTIDE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE CULTURE; TUMOR SPHEROID;

EID: 84908376035     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.5     Document Type: Article

References (36)

1. Bennett, CF and Swayze, EE (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50: 259-293.
2. Musacchio, T and Torchilin, VP (2013). siRNA delivery: from basics to therapeutic applications. Front Biosci (Landmark Ed) 18: 58-79.
3. Zhu, L and Mahato, RI (2010). Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv 7: 1209-1226.
4. Kaneda, Y (2010). Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 7: 1079-1093.
5. De Rosa, G and La Rotonda, MI (2009). Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 14: 2801-2823.
6. Juliano, R, Bauman, J, Kang, H and Ming, X (2009). Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6: 686-695.
7. Juliano, RL, Carver, K, Cao, C and Ming, X (2013). Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J Drug Target 21: 27-43.
8. Maeda, H, Nakamura, H and Fang, J (2013). The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65: 71-79.
9. Kostarelos, K, Emfietzoglou, D, Papakostas, A, Yang, WH, Ballangrud, A and Sgouros, G (2004). Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 112: 713-721.
10. Li, L, Sun, J and He, Z (2013). Deep penetration of nanoparticulate drug delivery systems into tumors: challenges and solutions. Curr Med Chem 20: 2881-2891.
11. Waite, CL and Roth, CM (2012). Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng 40: 21-41.
12. Friedrich, J, Seidel, C, Ebner, R and Kunz-Schughart, LA (2009). Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4: 309-324.
13. Oloumi, A, Lam, W, Banáth, JP and Olive, PL (2002). Identification of genes differentially expressed in V79 cells grown as multicell spheroids. Int J Radiat Biol 78: 483-492.
14. Smalley, KS, Lioni, M and Herlyn, M (2006). Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim 42: 242-247.
15. Kunz-Schughart, LA (1999). Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell Biol Int 23: 157-161.
16. Hirschhaeuser, F, Menne, H, Dittfeld, C, West, J, Mueller-Klieser, W and Kunz- Schughart, LA (2010). Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 148: 3-15.
17. Friedrich, J, Ebner, R and Kunz-Schughart, LA (2007). Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge? Int J Radiat Biol 83: 849-871.
18. Ivascu, A and Kubbies, M (2007). Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol 31: 1403-1413.
19. Alam, MR, Dixit, V, Kang, H, Li, ZB, Chen, X, Trejo, J et al. (2008). Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res 36: 2764-2776.
20. Popovic, Z, Liu, W, Chauhan, VP, Lee, J, Wong, C, Greytak, AB et al. (2010). A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl 49: 8649-8652.
21. Tang, L, Gabrielson, NP, Uckun, FM, Fan, TM and Cheng, J (2013). Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. Mol Pharm 10: 883-892.
22. Ming, X, Sato, K and Juliano, RL (2011). Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J Control Release 153: 83-92.
23. Ming, X, Carver, K, Fisher, M, Noel, R, Cintrat, JC, Gillet, D et al. (2013). The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res 41: 3673-3687.
24. Juliano, RL, Ming, X and Nakagawa, O (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem 23: 147-157.
25. Ming, X, Carver, K and Wu, L (2013). Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials 34: 7939-7949.
26. Minchinton, AI and Tannock, IF (2006). Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
27. Johnson, JI, Decker, S, Zaharevitz, D, Rubinstein, LV, Venditti, JM, Schepartz, S et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431.
28. Sharma, SV, Haber, DA and Settleman, J (2010). Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10: 241-253.
29. Fracasso, G and Colombatti, M (2000). Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 36: 159-178.
30. Lama, R, Zhang, L, Naim, JM, Williams, J, Zhou, A and Su, B (2013). Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing. Bioorg Med Chem 21: 922-931.
31. Waite, CL and Roth, CM (2011). Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density. Biotechnol Bioeng 108: 2999-3008.
32. Gil-Cardeza, ML, Villaverde, MS, Fiszman, GL, Altamirano, NA, Cwirenbaum, RA, Glikin, GC et al. (2010). Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Ther 17: 26-36.
33. Waite, CL and Roth, CM (2009). PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem 20: 1908-1916.
34. Kang, SH, Cho, MJ and Kole, R (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37: 6235-6239.
35. Alam, MR, Ming, X, Dixit, V, Fisher, M, Chen, X and Juliano, RL (2010). The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides 20: 103-109.
36. Timmins, NE and Nielsen, LK (2007). Generation of multicellular tumor spheroids by the hanging-drop method. Methods Mol Med 140: 141-151.